



# Correction to: Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis

Heini Pohjankoski<sup>1</sup> · Hannu Kautiainen<sup>2,3</sup> · Juhani Virta Lauri<sup>4</sup> · Kari Puolakka<sup>5</sup> · Vappu Rantalaiho<sup>6</sup>

Published online: 3 December 2019

© International League of Associations for Rheumatology (ILAR) 2019

## Correction to: *Clinical Rheumatology*

<https://doi.org/10.1007/s10067-019-04702-2>

The original version of this article, unfortunately, contained an error.

The given names and family names of the authors were interchanged and are now presented correctly. The original article has been corrected.

---

The online version of the original article can be found at <https://doi.org/10.1007/s10067-019-04702-2>

---

✉ Heini Pohjankoski  
heini.pohjankoski@sci.fi; heini.pohjankoski@pshyky.fi

Hannu Kautiainen  
hannu.kautiainen@medcare.fi

Juhani Virta Lauri  
lauri.virta@kela.fi

Kari Puolakka  
kari.puolakka@fimnet.fi

Vappu Rantalaiho  
vappu.rantalaiho@tuni.fi; vappu.rantalaiho@pshp.fi

<sup>1</sup> Department of Pediatrics, Päijät-Häme Central Hospital, Lahti, Finland

<sup>2</sup> Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland

<sup>3</sup> Folkhälsan Research Center, Helsinki, Finland

<sup>4</sup> Kela Research, The Social Insurance Institution of Finland, Turku, Finland

<sup>5</sup> Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland

<sup>6</sup> Centre for Rheumatic Diseases, Tampere University Hospital, and Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland